{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-22-082228","form_type":"8-K","ticker":"CTXR","cik":"0001506251","company_name":"Citius Pharmaceuticals, Inc.","filed_at":"2022-12-22T23:59:59+00:00","discovered_at":"2026-05-14T18:03:50.904934+00:00","generated_at":"2026-06-21T00:01:51.661201+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Citius Pharma reports FY2022 net loss $33.6M; cash $41.7M, I/ONTAK PDUFA July 2023","bullets":["Net loss $33.6M ($0.23/shr) vs $23.1M ($0.23/shr) prior year; R&D expenses up $5.5M to $17.7M.","Cash and equivalents $41.7M as of Sept 30, 2022; estimated runway through December 2023.","I/ONTAK BLA accepted by FDA; PDUFA target action date set for July 28, 2023.","Mino-Lok Phase 3: 169 patients enrolled, 72 of 92 failure events achieved, 17 patients pending.","Halo-Lido Phase 2b enrollment ongoing; data readout expected in second half 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-22-082228","json":"https://secwatch.observer/filing/0001213900-22-082228.json","markdown":"https://secwatch.observer/filing/0001213900-22-082228.md","text":"https://secwatch.observer/filing/0001213900-22-082228.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1506251/000121390022082228/0001213900-22-082228-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1506251/000121390022082228/ea170685-8k_citius.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-21T00:01:51.661201+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"b71baf1b550a9d9bf772be6868fac02edcfd7f9b","claim":"Citius Pharmaceuticals, Inc. reported the fiscal full year ended September 30, 2022 results: net income $33.6 million, EPS ($0.23) per share.","evidence_excerpt":"Net loss was $33.6 million, or ($0.23) per share for the full year ended September 30, 2022 compared to a net loss of $23.1 million, or ($0.23) per share for the full year ended September 30, 2021.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1506251/000121390022082228/0001213900-22-082228-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the fiscal full year ended September 30, 2022"},{"label":"Net income","value":"$33.6 million"},{"label":"EPS","value":"($0.23) per share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}